CHMP approves Briviact extended indications
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, the BelgianPharmaceutical(UCB) announced that the EuropeanPharmaceutical(EMA) for humanmedicines(
CHMP) has issued a positive opinion recommending the approval of Briviact (brivaracetam) extended indications to include complementary treatment for people with epilepsy 4 years and older with partial seizures (accompanied by or uneniumed secondary seizures)BriviactBriviact is the mostnew drugin the family ofdrugs found and developed by Uber, the synaptic cystic protein 2A (SV2A) anti-epileptic drug (AED)Briviact exhibits a high degree of selective affinity for SV2A in the brain and can be absorbed quickly and completely, which may help with its anticonvulsion stoicismHowever, the exact mechanism by which Briviact acts as anticonvulsant is not yet knownCHMP's positive advice is based on the efficacy data of Briviact for adult patients and is supported by safety and pharmacokinetic data collected in child patientsExtrapolating clinical data from good controlled studies in adults has been recognized by the EMA to potentially address the challenges of limited pediatric data availability in the European Union, Briviact is currently approved for the treatment of partial seizures (with or without secondary seizures) in adolescents and adults aged 16 and over in the United States, Briviact was approved in May for treatment of partial seizures in people with epilepsy ages 4 and older
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
